Thursday, May 16, 2019
Mechanism on patients who dont respond to Kadcyla
Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancerinduces ROR1 and confers resistance through activation of Hippotranscriptional coactivator YAP1
This is a pretty interesting paper trying to identify why some patients don't respond to T-DM1 based therapy. After demonstrating an increased expression of ROR1 resulting from T-DM1 administration, they demonstrate that inhibiting ROR1 could be a potential treatment for these patients.
Pretty cool stuff.